BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 29150249)

  • 21. Real-World Data of the Correlation between EGFR Determination by Liquid Biopsy in Non-squamous Non-small Cell Lung Cancer (NSCLC) and the EGFR Profile in Tumor Biopsy.
    Soria-Comes T; Palomar-Abril V; Ureste MM; Guerola MT; Maiques ICM
    Pathol Oncol Res; 2020 Apr; 26(2):845-851. PubMed ID: 30847713
    [TBL] [Abstract][Full Text] [Related]  

  • 22. EGFR Mutations in Cell-free Plasma DNA from Patients with Advanced Lung Adenocarcinoma: Improved Detection by Droplet Digital PCR.
    Buder A; Setinek U; Hochmair MJ; Schwab S; Kirchbacher K; Keck A; Burghuber OC; Pirker R; Filipits M
    Target Oncol; 2019 Apr; 14(2):197-203. PubMed ID: 30810887
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical performance evaluation of the Idylla™ EGFR Mutation Test on formalin-fixed paraffin-embedded tissue of non-small cell lung cancer.
    Delgado-García M; Weynand B; Gómez-Izquierdo L; Hernández MJ; Blanco ÁM; Varela M; Matias-Guiu X; Nadal E; Márquez-Lobo B; Alarcão A; de Álava E; Biscuola M
    BMC Cancer; 2020 Apr; 20(1):275. PubMed ID: 32245434
    [TBL] [Abstract][Full Text] [Related]  

  • 24. EGFR Mutational Profiling in Non-Small Cell Lung Cancer: The Clinical Performance of a Sensitive Reverse-Hybridization Assay.
    Kriegshäuser G; Enko D; Novy M; Reitmayr A; Loidl A; Halwachs-Baumann G; Oberkanins C
    Appl Immunohistochem Mol Morphol; 2018 Jul; 26(6):388-392. PubMed ID: 27801728
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of epidermal growth factor receptor mutation detection turnaround times and concordance among real-time polymerase chain reaction, high-throughput next-generation sequencing and the Biocartis Idylla™ platforms in non-small cell lung carcinomas.
    Sharma S; Satapathy A; Aggarwal A; Dewan A; Jain E; Katara R; Kumar V; Pal R; Pandey S; Naidu MM; Kini L; Pradhan D; Mohanty SK
    Pathol Res Pract; 2021 Apr; 220():153394. PubMed ID: 33706124
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Detection of EGFR mutations in patients with non-small cell lung cancer by high resolution melting. Comparison with other methods.
    Martínez-Carretero C; Pascual FI; Rus A; Bernardo I
    Clin Chem Lab Med; 2017 Oct; 55(12):1970-1978. PubMed ID: 28432840
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Direct serum and tissue assay for EGFR mutation in non-small cell lung cancer by high-resolution melting analysis.
    Hu C; Liu X; Chen Y; Sun X; Gong Y; Geng M; Bi L
    Oncol Rep; 2012 Nov; 28(5):1815-21. PubMed ID: 22923193
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of different platforms in detecting EGFR mutations using cerebrospinal fluid cell-free DNA from non-small-cell lung cancer patients with leptomeningeal metastases.
    Chiang CL; Ho HL; Yeh YC; Lee CC; Huang HC; Shen CI; Luo YH; Chen YM; Chiu CH; Chou TY
    Thorac Cancer; 2023 May; 14(14):1251-1259. PubMed ID: 36977550
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of next-generation sequencing and cobas EGFR mutation test v2 in detecting EGFR mutations.
    Murakami S; Yokose T; Shinada K; Isaka T; Katakura K; Ushio R; Kondo T; Kato T; Ito H; Saito H
    Thorac Cancer; 2022 Nov; 13(22):3217-3224. PubMed ID: 36203199
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Peptide Nucleic Acid Clamping Versus Direct Sequencing for the Detection of EGFR Gene Mutation in Patients with Non-small Cell Lung Cancer.
    Yoon SH; Choi YD; Oh IJ; Kim KS; Choi H; Chang J; Shin HJ; Park CK; Kim YC
    Cancer Res Treat; 2015 Oct; 47(4):661-9. PubMed ID: 25715768
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Profile of the therascreen® EGFR RGQ PCR kit as a companion diagnostic for gefitinib in non-small cell lung cancer.
    Hsiue EH; Lee JH; Lin CC; Yang JC
    Expert Rev Mol Diagn; 2016 Dec; 16(12):1251-1257. PubMed ID: 27737606
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The "COLD-PCR approach" for early and cost-effective detection of tyrosine kinase inhibitor resistance mutations in EGFR-positive non-small cell lung cancer.
    Mairinger FD; Vollbrecht C; Streubel A; Roth A; Landt O; Walter HF; Kollmeier J; Mairinger T
    Appl Immunohistochem Mol Morphol; 2014; 22(2):114-8. PubMed ID: 24517913
    [TBL] [Abstract][Full Text] [Related]  

  • 33. EGFR mutational genotyping of liquid based cytology samples obtained via fine needle aspiration (FNA) at endobronchial ultrasound of non-small cell lung cancer (NSCLC).
    Reynolds JP; Tubbs RR; Minca EC; MacNamara S; Almeida FA; Ma PC; Pennell NA; Cicenia JC
    Lung Cancer; 2014 Nov; 86(2):158-63. PubMed ID: 25263855
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detection of rare and novel EGFR mutations in NSCLC patients: Implications for treatment-decision.
    Sousa AC; Silveira C; Janeiro A; Malveiro S; Oliveira AR; Felizardo M; Nogueira F; Teixeira E; Martins J; Carmo-Fonseca M
    Lung Cancer; 2020 Jan; 139():35-40. PubMed ID: 31715539
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A multicenter blinded study evaluating EGFR and KRAS mutation testing methods in the clinical non-small cell lung cancer setting--IFCT/ERMETIC2 Project Part 1: Comparison of testing methods in 20 French molecular genetic National Cancer Institute platforms.
    Beau-Faller M; Blons H; Domerg C; Gajda D; Richard N; Escande F; Solassol J; Denis MG; Cayre A; Nanni-Metellus I; Olschwang S; Lizard S; Piard F; Pretet JL; de Fraipont F; Bièche I; de Cremoux P; Rouquette I; Bringuier PP; Mosser J; Legrain M; Voegeli AC; Saulnier P; Morin F; Pignon JP; Zalcman G; Cadranel J
    J Mol Diagn; 2014 Jan; 16(1):45-55. PubMed ID: 24183959
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Application of amplicon-based targeted sequencing with the molecular barcoding system to detect uncommon minor EGFR mutations in patients with treatment-naïve lung adenocarcinoma.
    Namba K; Tomida S; Matsubara T; Takahashi Y; Kurihara E; Ogoshi Y; Yoshioka T; Takeda T; Torigoe H; Sato H; Shien K; Yamamoto H; Soh J; Tsukuda K; Toyooka S
    BMC Cancer; 2019 Feb; 19(1):175. PubMed ID: 30808329
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Implementation of next generation sequencing technology for somatic mutation detection in routine laboratory practice.
    Giardina T; Robinson C; Grieu-Iacopetta F; Millward M; Iacopetta B; Spagnolo D; Amanuel B
    Pathology; 2018 Jun; 50(4):389-401. PubMed ID: 29752127
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Droplet digital PCR-based EGFR mutation detection with an internal quality control index to determine the quality of DNA.
    Kim SS; Choi HJ; Kim JJ; Kim MS; Lee IS; Byun B; Jia L; Oh MR; Moon Y; Park S; Choi JS; Chae SW; Nam BH; Kim JS; Kim J; Min BS; Lee JS; Won JK; Cho SY; Choi YL; Shin YK
    Sci Rep; 2018 Jan; 8(1):543. PubMed ID: 29323170
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison study of the performance of the QIAGEN EGFR RGQ and EGFR pyro assays for mutation analysis in non-small cell lung cancer.
    Cushman-Vokoun AM; Crowley AM; Rapp SA; Greiner TC
    Am J Clin Pathol; 2013 Jul; 140(1):7-19. PubMed ID: 23765529
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Profile of the Roche cobas® EGFR mutation test v2 for non-small cell lung cancer.
    Malapelle U; Sirera R; Jantus-Lewintre E; Reclusa P; Calabuig-Fariñas S; Blasco A; Pisapia P; Rolfo C; Camps C
    Expert Rev Mol Diagn; 2017 Mar; 17(3):209-215. PubMed ID: 28129709
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.